Skip to main content

Table 3 Summary of health state utility values

From: A time trade-off study to determine health-state utilities of transplant recipients with refractory cytomegalovirus infection with or without resistance

Health state category

Health state

Number of respondents valuing health state

Mean utility

(95% CI)

Median utility

(SE)

Clinical health states

CS-symptomatic CMV

738

0.443

(0.404, 0.482)

0.500 (0.020)

CS-asymptomatic CMV

738

0.635

(0.602, 0.669)

0.800 (0.017)

Non-CS CMV

738

0.815

(0.791, 0.839)

0.975 (0.012)

Clinical health states with GvHD

CS-symptomatic CMV with GvHD

738

0.391

(0.350, 0.432)

0.500 (0.021)

CS-asymptomatic CMV with GvHD

738

0.486

(0.446, 0.525)

0.625 (0.020)

Non-CS CMV with GvHD

738

0.552

(0.514, 0.590)

0.700 (0.019)

Clinical health states with kidney GL

CS-symptomatic CMV with kidney GL

376

0.363

(0.303, 0.424)

0.500 (0.031)

CS-asymptomatic CMV with kidney GL

376

0.470

(0.414, 0.526)

0.563 (0.028)

Non-CS CMV with kidney GL

376

0.531

(0.480, 0.582)

0.650 (0.026)

Clinical health states with lung GL

CS-symptomatic CMV with lung GL

362

0.289

(0.226, 0.352)

0.450 (0.032)

CS-asymptomatic CMV with lung GL

362

0.356

(0.290, 0.422)

0.500 (0.034)

Non-CS CMV with lung GL

362

0.376

(0.312, 0.440)

0.500 (0.033)

  1. CMV cytomegalosvirus, CS-asymptomatic CMV clinically significant and asymptomatic CMV, CS-symptomatic CMV clinically significant and symptomatic CMV, GvHD graft-versus-host disease, GL graft loss, non-CS CMV non-clinically significant CMV, SD standard deviation, SE standard error, CI confidence interval